ArticleFrontiers in oncology2026
Case Report: Sellar collision tumor consisting of pituitary adenoma and craniopharyngioma, with literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collision tumors harbor two distinct histological features at the same site, and sellar collision tumors of pituitary adenoma (PA) and craniopharyngioma (CP) are extremely rare. This report presents a 64-year-old female with fatigue, anorexia, palpitations, dizziness, and exertional dyspnea. Examinations confirmed pan-hypopituitarism and life-threatening electrolyte disturbances. Preoperative MRI showed a homogeneous lesion indistinguishable from a standard macroadenoma. She underwent neuroendoscopic transsphenoidal resection. Intraoperatively, the tumor exhibited a fibrous, tough consistency with no discernible boundary between components, resulting in a "blind" resection of the collision pathology. Significant cavernous sinus hemorrhage (800 mL) occurred due to severe adhesion. Postoperatively, hormone replacement therapy was administered, with stable recovery and discharge on day 18. Pathology confirmed a collision of Null-cell adenoma and Adamantinomatous CP. This case highlights the diagnostic pitfall of "occult" collision tumors where imaging and surgical texture fail to differentiate components, necessitating comprehensive immunohistochemistry. Few similar cases have been reported, mostly involving non-functional PA and adamantinomatous CP with diverse pathogenesis hypotheses. This case supplements critical clinical data on diagnosis, surgical management, and prognosis of this rare sellar tumor, highlighting therapeutic considerations for neurosurgery clinicians.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.